CP
EDIT icon

Corbenic Partners’s Editas Medicine EDIT Stock Holding History

Corbenic Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$2K Hold
141
– – ﹤0.01% 177
2022
Q1 		$3K Hold
141
– – ﹤0.01% 196
2021
Q4 		$4K Buy
141
+81
+135% +$2.79K ﹤0.01% 220
2021
Q3 		$2K Hold
60
– – ﹤0.01% 250
2021
Q2 		$3K Buy
+60
New +$2.22K ﹤0.01% 221

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Corbenic Partners's EDIT Position: Q2 2022 in Review

Corbenic Partners held its Editas Medicine (EDIT) position steady in Q2 2022 at 141 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #177.

Corbenic Partners first reported a position in EDIT in Q2 2021 and has held it in 5 quarters since. The position peaked at $4K in Q4 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

  • Corbenic Partners held 141 shares of Editas Medicine worth $2K as of Q2 2022.
  • Corbenic Partners left its Editas Medicine share count unchanged in Q2 2022.
  • Editas Medicine made up ﹤0.01% of Corbenic Partners's portfolio in Q2 2022, its #177 holding.
  • Corbenic Partners first reported a position in Editas Medicine in Q2 2021 and has held it in 5 quarters since.
  • Corbenic Partners's Editas Medicine position peaked at $4K in Q4 2021.
  • 256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.